Evidence map›Paper›PMID 42131993›Full record

ArticleChemistry & biodiversity2026

Hui-Xiang Decoction Against Pancreatic Cancer by Regulating AKT and Activating the Hippo Signaling Pathway.

Jian Zhang, Nannan Tang, Ao Gu, Jiatong Li, Meng-Yao Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jian ZhangDepartment of Anesthesiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Nannan TangState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ao GuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiatong LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Meng-Yao LiState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-7054-448X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) is a devastating disease with high mortality and a pressing need for safer, less toxic therapies. This study identifies Hui-Xiang decoction (HXD), a formulation from food and medicine homology (FMH) herbs, as an effective and low-toxicity treatment. We identified the presence of 122 active ingredients and 12 PC associated targets in HXD by network pharmacology. HXD and its active component, ammidin, effectively inhibited the proliferation and migration of PC cells. Furthermore, treatment with HXD in clinically relevant patient-derived organoid (PDO) and xenograft (PDX) models significantly inhibited tumor growth, with minimal toxicity. Crucially, we found that HXD combats PC through a dual mechanism: simultaneously inhibiting the oncogenic EGFR/ErbB2/AKT1 pathway and activating the tumor-suppressive Hippo signaling pathway. These results not only elucidate the molecular basis for HXD's efficacy but also provide a strong rationale for its potential application in the management of PC.

Indexed as

AdenocarcinomaDrugs, Chinese HerbalHippo Signaling PathwayPancreatic NeoplasmsAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesErbB ReceptorsHumansMiceMice, NudeMolecular Docking SimulationNetwork PharmacologyOrganoidsProto-Oncogene Proteins c-aktXenograft Model Antitumor AssaysDrugs, Chinese HerbalEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsProto-Oncogene Proteins c-aktEGFR/ErbB2/AKT1 axisfood and medicine homologyHippo signaling pathwayHui‐Xiang decoctionpatient‐derived organoidspatient‐derived xenografts

Identifiers

PMID42131993
PMCPMC13376994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.